Brean Capital Boosts Onyx Pharma (ONXX) Price Target to $160
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Bidding for Onyx Pharma (ONXX) Done? Not Likely...
July 3, 2013 7:38 AM EDTOnyx Pharmaceuticals (Nasdaq: ONXX) recently surged on disclosure that Amgen (Nasdaq: AMGN) approachd the company with a $120 per share takeover offer. Despite shares being up 13 percent over the bid and 56 percent since the close last Friday, is... More
Maxim Group Downgrades Onyx Pharmaceuticals (ONXX) to Hold
July 1, 2013 11:18 AM EDTMaxim Group downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold.
For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.
Shares of Onyx Pharmaceuticals closed at $86.82 yesterday, with a 52 week range of $63.00-$101.57.... More
Leerink Swann Raies Onyx (ONXX) Price Target to $140
July 1, 2013 9:34 AM EDTLeerink Swann today maintained an Outperform on Onyx Pharmaceuticals (NASDAQ: ONXX) and raised its price target to $140.00 (from $112). The change follows news of a $120 bid from Amgen (Nasdaq: AMGN).
Commenting, analyst Howard Liang said, "We see a... More
Onyx Pharma (ONXX) Reports $120/Share Bid from Amgen (AMGN); Hires Advisor
July 1, 2013 6:24 AM EDTOnyx Pharmaceuticals, Inc. (NASDAQ: ONXX) today confirmed that it has received and rejected an unsolicited proposal from Amgen Inc. (Nasdaq: AMGN) to acquire all of Onyx's outstanding shares and share equivalents for $120 per share in cash, subject to due diligence and other conditions. The Board of Directors of Onyx had evaluated the proposal made by Amgen with the assistance of its financial and legal advisors and concluded that... More
